Professor Kelly E. Dunn: Fighting Fentanyl with Naloxone: A lifeline Amid the Epidemic

Dr. Kathryn Najafi-Tagol, MD, Chief Medical Officer of Emery Pharma, introduced Professor Kelly E. Dunn of Johns Hopkins University at the recent Emery Pharma Speaker Series. Professor Dunn’s presentation focused on the essential role of naloxone in harm reduction and preventing opioid overdose fatalities. A prominent figure in addiction science and behavioral pharmacology, Professor Dunn’s research at Johns Hopkins centers on unraveling the complexities of opioid dependence and developing targeted interventions. Her impactful work has shaped both policy and clinical practices, advancing effective strategies for opioid treatment and overdose prevention.

About Emery Pharma:
Emery Pharma is deeply committed to advancing public health and exclusively focuses on projects that enhance the well-being of both individuals and the environment. As a comprehensive contract research laboratory, Emery Pharma provides extensive support across the entire spectrum of pharmaceutical development, covering small molecule drugs, biologics, biosimilars, gene therapy, botanicals, and more.

Emery Pharma's array of premium services includes analytical and bioanalytical solutions, microbiology and cell biology services, drug and impurity characterization, and comprehensive R&D with cGMP/GLP support. The Emery Pharma team excels in customizing innovative solutions tailored to the unique requirements of each client. They seamlessly oversee the entire process, from initial drug discovery to thorough data analysis and insights generation. Their expertise allows them to tackle scientific challenges proactively, ensuring clients avoid unnecessary setbacks.

Emery Pharma's accomplished chemists and biologists harness state-of-the-art technology, encompassing cutting-edge tools such as high-resolution mass spectrometry (Orbitrap), triple quad LC-MS/MS, GC-MS, preparative HPLC, and 400 MHz multinuclear NMR.